tbuckley/cabot-search huggingface dataset:
IMMU-33. IMMUNE PROFILING REVEALS INHIBITORY MACROPHAGES AND A DISTINCT SPATIAL DISTRIBUTION OF IMMUNE CELLS IN DIFFERENT TYPES OF BRAIN METASTASES
Authors: Jenny Kienzler, Jeremy Reynoso, Geoffrey Owens, Joey Orpilla, Alexander Lee, Aaron Mochizuki, William H Yong, Linda Liau, Robert Prins
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Current treatment modalities, including surgical resection, radiosurgery and immune checkpoint inhibitors, have improved local control rates of brain metastases, but overall prognosis is still poor. AIM: To investigate the immune microenvironment in brain metastases for better understanding of treatment failures. METHODS We identified 42 patients with melanoma (M), breast (B) and lung (L) brain metastases and performed multiplex immunofluorescent staining for immune markers (CD4, CD8, CD45, PD1, PD-L1) and quantitative analysis with HALO software. NanoString nCounter mRNA gene expression assay was used for identification of immune pathways. CyTOF and single cell RNA sequencing were done on 12 different brain metastases and their matched peripheral blood samples. RESULTS The median CD8, CD4 and PD1 density (as a total number of cells) was 0.24%, 0.13%, and 0.07% for M, 0.24%, 0.51% and 0.08% for B, and 0.87%, 1.36%, 0.67% for L. CD4 and CD8+PD1+ expression was significantly different between all groups (p=0.01), CD4+PD1+ in M vs. L (p=0.03) and PD1 in B vs. L (p=0.03). No significant difference was found in terms of CD45 positive cells (M 2.13%, B, 1.99%, L 4.95%). PD-L1 expression was significantly different between histologies; the highest expression was present in breast metastases (M: 1.51%, B: 49.98%, L: 31.90%, p=0.0002). Spatial distribution revealed a characteristic pattern with a peritumoral border infiltrate in M, and predominant intratumoral distribution in B and L (M 0.2%, B 2.6%, L 3.6%, p=0.02). CyTOF clustering demonstrated that macrophages are the most prevalent immune population overall (83.08%), with an inhibitory phenotype and gene expression pattern present in different histologies (S100A9, CCL20, IFI16, MARCO). T-cells (predominantly CD4+, 3.6%), and B-cells (1.5%) comprise the remaining immune cell populations. CONCLUSION Neoadjuvant targeted treatment approaches may be needed to alter predominance of inhibitory macrophages and recruit activated T lymphocytes in brain metastases.
Effects of Voxelotor (GBT440) Therapy on Laboratory Testing of Sickle Cell Patients
Authors: Michelle E. Savedra, Jessica L. Szuberski, Tavanna R. Porter, Molly S. Hein, Phuong L. Nguyen, Min Shi, Aruna Rangan, James D. Hoyer, Jennifer L. Oliveira
Journal: Blood (2019)
The Exosomal Transfer of Acid Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma
Authors: Inge Oudaert, Sylvia Faict, Ludovic D'Auria, Jonas Dehairs, Ken Maes, Philip Vlummens, Lotte Jacobs, Kim De Veirman, Elke De Bruyne, Karel Fostier, Isabelle Vande Broek, Rik Schots, Karin Vanderkerken, Johannes V. Swinnen, Eline Menu
Journal: Blood (2019)
Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia
Authors: Gauri Deb, Bettina Wingelhofer, Fabio M. R. Amaral, Alba Maiques-Diaz, John A. Chadwick, Gary J. Spencer, Emma L. Williams, Hui-Sun Leong, Tamara Maes, Tim C. P. Somervaille
Journal: Leukemia (2019)

Abstract The histone demethylase lysine-specific demethylase 1 (LSD1 or KDM1A) has emerged as a candidate therapeutic target in acute myeloid leukaemia (AML); tranylcypromine-derivative inhibitors induce loss of clonogenic activity and promote differentiation, in particular in the MLL -translocated molecular subtype of AML. In AML, the use of drugs in combination often delivers superior clinical activity. To identify genes and cellular pathways that collaborate with LSD1 to maintain the leukaemic phenotype, and which could be targeted by combination therapies, we performed a genome-wide CRISPR-Cas9 dropout screen. We identified multiple components of the amino acid sensing arm of mTORC1 signalling—RRAGA, MLST8, WDR24 and LAMTOR2—as cellular sensitizers to LSD1 inhibition. Knockdown of mTORC1 components, or mTORC1 pharmacologic inhibition, in combination with LSD1 inhibition enhanced differentiation in both cell line and primary cell settings, in vitro and in vivo, and substantially reduced the frequency of clonogenic primary human AML cells in a modelled minimal residual disease setting. Synergistic upregulation of a set of transcription factor genes associated with terminal monocytic lineage differentiation was observed. Thus, dual mTORC1 and LSD1 inhibition represents a candidate combination approach for enhanced differentiation in MLL -translocated AML which could be evaluated in early phase clinical trials.
A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas
Authors: Peter A. Riedell, Chase Walling, Loretta J. Nastoupil, Martina Pennisi, Richard T. Maziarz, Joseph P. McGuirk, Olalekan O. Oluwole, Veronika Bachanova, Wei-Ting Hwang, Stephen J. Schuster, Miguel-Angel Perales, Michael R. Bishop, David L. Porter
Journal: Blood (2019)
Phenotypic Corrections of Ex Vivo Erythrocytes Derived from Chronic Hemolytic Anemia Patients Due to Krϋppel-like Factor 1 (KLF-1) Mutations By AG-348: A Novel Synthetic Pyruvate Kinase Activator
Authors: Thidarat Suksangpleng, Kalaya Tachavanich, Suchada Riolueang, Supachai Ekwattanakit, Vip Viprakasit
Journal: Blood (2019)
Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network
Authors: Uwe Platzbecker, Anne Sophie Kubasch, Aristoteles Giagounidis, Georgia Metzgeroth, Anna Jonasova, Regina Herbst, Jose Miguel Torregrosa Diaz, Benoit De Renzis, Katharina Götze, Marie-Luise Huetter-Kroenke, Marie-Pierre Gourin, Borhane Slama, Sophie Dimicoli-Salazar, Pascale Cony-Makhoul, Kamel Laribi, Sophie Park, Katja Jersemann, Oliver Tiebel, Katja Sockel, Silke Gloaguen, Anna Mies, Fatiha Chermat, Christian Thiede, Rosa Sapena, Richard F. Schlenk, Pierre Fenaux, Lionel Ades
Journal: Blood (2019)
Correlation of Flow Cytometric Aberrations with Cytogenetic, Molecular Genetic, and Morphology in Patients with Unexplained Cytopenias
Authors: Haya Azouz, Jessica Ternus, Phuong L. Nguyen, Dragan Jevremovic, Mrinal M Patnaik, Michael M. Timm, Min Shi, Rong He, David S. Viswanatha, Mithun Vinod Shah, Hassan B. Alkhateeb, Naseema Gangat, Kebede H. Begna, William J Hogan, Mark Litzow, Cindy Hengel, Aref Al-Kali
Journal: Blood (2019)
Hyperactive Nras and Dose Reduction of Tet2 Collaborate to Dys-Regulate Hematopoietic Stem Cells and Promote Leukemogenesis
Authors: Xi Jin, Tingting Qin, Nathanael G Bailey, Meiling Zhao, Kevin B Yang, Victor Ng, Lu Liu, Rosemary Coolon, Gina Ney, Maria E Figueroa, Qing Li
Journal: Blood (2016)
Higher Order Restrictions of the Immunoglobulin Repertoire in CLL: The Illustrative Case of Stereotyped Subsets #2 and #169
Authors: Katerina Gemenetzi, Andreas Agathangelidis, Fotis Psomopoulos, Karla Plevova, Lesley-Ann Sutton, Kostas Pasentsis, Achilles Anagnostopoulos, Raphael Sandaltzopoulos, Richard Rosenquist, Frederic Davi, Sarka Pospisilova, Kostas Stamatopoulos, Anastasia Chatzidimitriou
Journal: Blood (2019)
Fully Closed, Large-Scale, and Clinical Grade Cell Sorting of Hematopoietic Stem Cell (HSC)-Enriched CD90+ Cells for Transplantation and Gene Therapy
Authors: Stefan Radtke, Margaret Cui, Anai M Perez, Yan-Yi Chan, Stefanie Schmuck, Andrew J Berger, Thomas Eunson, Hans-Peter Kiem
Journal: Blood (2019)
A Common HLA Allelic Mutation of exon1 in Leukocytes Defines Class I Alleles Responsible for Autoantigen Presentation of Acquired Aplastic Anemia
Authors: Hiroki Mizumaki, Kazuyoshi Hosomichi, Tatsuya Imi, Noriaki Tsuji, Tanabe Mikoto, Dung Cao Tran, Kohei Thi Hosokawa, Yoshitaka Zaimoku, Kohei Hosokawa, Takamasa Katagiri, Fumihiro Azuma, Atsushi Tajima, Shinji Nakao
Journal: Blood (2019)
Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G‐CSF or G‐CSF and plerixafor mobilized grafts
Authors: Harsh Shah, Seongho Kim, Paramveer Singh, Asif Alavi, Voravit Ratanatharathorn, Lois Ayash, Joseph Uberti, Abhinav Deol
Journal: American Journal of Hematology (2019)

Impact of Plerixafor (P) mobilized stem cells on immune reconstitution, such as absolute lymphocyte count at day 30 (ALC30), and on long-term outcomes of Multiple Myeloma (MM) patients undergoing autologous stem cell transplant (ASCT) has not been well established. We evaluated total of 469 patients mobilized with G-CSF (G) alone, and 141 patients mobilized with G-CSF plus plerixafor (G+ P). Patients only received plerixafor if they had peripheral blood CD34+ blood count <20/μL on first planned day of collection. Primary endpoint, ALC30, was 1.3 K/μL (range, 0.1-4.5) and 1.2 K/μL (range, 0.1-5.1) for G and G + P, respectively (P =. 61). The median PFS was 2.5 years (95% CI, 2.1-3.2) and 2.8 years (95% CI, 2.0-3.3) for G and G + P, respectively (HR: 1.13; 95% CI, 0.84-1.50; P = .42). The median OS was 6.1 years (95% CI, 4.6-NR) for G group compared to 3.7 years (95% CI, 3.2-NR) for the G + P group (HR: 1.64; 95% CI, 1.12-2.40; P = .01). The median follow-up time for OS was 2.53 years (95% CI, 2.13-2.99) and 1.59 years (95% CI, 1.17-2.02) for G and G+ P group, respectively. In this large retrospective analysis of MM patients mobilized with G-CSF vs G-CSF + P, there was no significant difference in lymphocyte recovery or PFS. There was an overall survival difference in patients who were poor mobilizers and could not be mobilized with G-CSF alone.
Future of General Practice
Authors: R. L. H. Jones
Journal: BMJ (1964)

Mucosal-associated invariant T (MAIT) cells are innate-like T cells that acquire an effector function and differentiate into MAIT1 (T-bet<sup>+</sup>) and MAIT17 (RORγt<sup>+</sup>) subsets prior to thymic export. Upon activation, MAIT cells quickly release IFN-γ and IL-17, which modulate a broad spectrum of diseases, including autoimmunity, infection, allergy and cancer. miRNAs are no-coding RNAs regulating immune cell development and function. A recent study indicated defective MAIT cell development in the miRNAs-deficient mice, but, the specific miRNAs that guide their development remain unclear. Previous studies indicated that miR-17-92 regulates different immune cell development and function, however, the role of miR-17-92 in the MAIT cell development remains unclear. Here, we generated T cell specific miR-17-92 knockout (KO) mice to test the role of miR-17-92 in MAIT cell development and function. We found that deletion of miR-17-92 led to a profound defect on the MAIT cells in the number and frequencies in the thymus and peripheral immune organs, including spleen, lymph nodes, and liver, as well as in the lung and peritoneal cavity (P&lt;0.05). The frequency of MAIT17 cells was dramatically reduced in miR-17-92 KO mice, while the frequency of MAIT1 cells was dramatically increased in thymic and peripheral immune organs, compared to wild-type (WT) controls. Furthermore, upon PMA/Ionomycin stimulation, we found a defect of IL-17 production, with significantly increased IFN-γ production by peripheral MAIT cells in miR-17-92 KO mice, compared to WT controls. The detailed miR-17-92 targeting pathway by RNA-Seq and Chip-Seq is under the investigation. Overall, our data indicated that miR-17-92 plays a pivotal role in MAIT cell development and function.
Leukotriene B4 receptors abnormal gene expression is associated with either shorter or longer survival in breast cancer patients depending on the intrinsic tumour molecular subtype
Authors: A.I. Kalinkin, M.V. Nemtsova, D.V. Zaletaev, V.O. Sigin, E. Ignatova, E.B. Kuznetsova, V.V. Strelnikov, A.S. Tanas
Journal: Annals of Oncology (2019)
Implementation of the Peripherally Inserted Central Venous Catheter for Patients with Hematological Malignancies in a Peruvian Cancer Center
Authors: Katia Roque, Daniel J Enriquez, Elera Elizabeth, Emperatriz Ortega, Juan C Haro, Nathaly Poma, Ricardo Ponce, Indira Tirado-Hurtado, Silvia Neciosup, Henry Gomez
Journal: Blood (2019)
GENE-58. ACTIVE TRANSCRIPTION START SITES OF MENINGIOMA SAMPLES ASSOCIATED WITH RISK OF RECURRENCE
Authors: Tathiane Malta, Thais Sarraf Sabedot, Carlos Carlotti jr, Houtan Noushmehr
Journal: Neuro-Oncology (2019)

Abstract Meningiomas are mostly benign brain tumors but have a substantial risk of recurrence, sometimes to more aggressive subtypes. Recently, a DNA methylation signature in meningioma was described as able to stratify patients by recurrence risk (favorable and unfavorable). It is well recognized that epigenetic deregulation at distinct genomic elements can affect changes in gene expression and contribute to cancer initiation and progression. Our goal for this study is to define genes that are actively expressed or repressed by both DNA methylation and chromatin histone modification (defined by H3K4me3). For this pilot study, we selected two favorable (grades I and II) and two unfavorable (grades II and III) meningioma primary tumor samples (N=4) and mapped H3K4me3 genome-wide and whole-genome DNA methylation, in an attempt to identify active transcription start sites at known promoters. After data alignment, preprocessing and peak calling, we identified 29,514 consensus peaks for H3K4me3. The differential binding analysis resulted in 5,752 H3K4me3 regions that distinguish favorable from unfavorable meningioma, mostly gain of peaks in the unfavorable group. We identified 1,505 peaks overlapping with known promoters, 51% associated with gain of peaks in the unfavorable group. Promoter-associated chromatin changes coincided with hypomethylation in 23 unique genes in the unfavorable group. Genes such as MET, PTEN, and the long non-coding RNA RP11-60L3.1 were identified as potential regulators of meningioma recurrence. Our preliminary results describe the identification of distinct genome-wide changes in chromatin associated with meningioma patient with high risk for recurrence. Identification of candidate genes will provide knowledge of the role of epigenomics in the development of malignant meningioma and of opportunities for targeted therapy.
Disparities in Receipt of Eye Exams Among Medicare Part B Fee-for-Service Beneficiaries with Diabetes — United States, 2017
Authors: Elizabeth A. Lundeen, John Wittenborn, Stephen R. Benoit, Jinan Saaddine
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

Approximately 30 million persons in the United States have diabetes.* Persons with diabetes are at risk for vision loss from diabetic retinopathy and other eye diseases (1). Diabetic retinopathy, the most common diabetes-related eye disease, affects 29% of U.S. adults aged ≥40 years with diabetes (2) and is the leading cause of incident blindness among working-age adults (1). It is caused by chronically high blood glucose damaging blood vessels in the retina.† Annual dilated eye exams are recommended for persons with diabetes because early detection and timely treatment of diabetic eye diseases can prevent irreversible vision loss§,¶ (3,4). Studies have documented prevalence of annual eye exams among U.S. adults with diabetes (5,6); however, a lack of recent state-level data limits identification of geographic disparities in adherence to this recommendation. Medicare claims from the 50 states, the District of Columbia (DC), Puerto Rico, and U.S. Virgin Islands (USVI) were examined to assess the prevalence of eye exams in 2017 among beneficiaries with diabetes who were continuously enrolled in Part B fee-for-service insurance, which covers annual eye exams for beneficiaries with diabetes.** This report also examines disparities, by state and race/ethnicity, in receipt of eye exams. Nationally, 54.1% of beneficiaries with diabetes had an eye exam in 2017. Prevalence ranged from 43.9% in Puerto Rico to 64.8% in Rhode Island. Fewer than 50% of beneficiaries received an eye exam in seven states (Alabama, Alaska, Kentucky, Louisiana, Nevada, West Virginia, and Wyoming) and Puerto Rico. Non-Hispanic white (white) beneficiaries had a higher prevalence of receiving an eye exam (55.6%) than did non-Hispanic blacks (blacks) (48.9%) and Hispanics (48.2%). Barriers to receiving eye care (e.g., suboptimal clinical care coordination and referral, low health literacy, and lack of perceived need for care) might limit Medicare beneficiaries' ability to follow this preventive care recommendation. Understanding and addressing these barriers might prevent irreversible vision loss among persons with diabetes.
Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation
Authors: Cindy Lynn Hickey, Haesook T. Kim, Sarah Nikiforow, Mahasweta Gooptu, John Koreth, Jerome Ritz, Vincent T. Ho, Edwin P. Alyea, Robert J. Soiffer, Joseph H. Antin, Corey Cutler, Rizwan Romee
Journal: Blood (2019)
ATIM-01. NIVOLUMAB AND BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA; A TRANSLATIONAL TRIAL IN PROGRESS
Authors: Simone Eibye, Benedikte Hasselbalch, Inge Marie Svane, Sine Reker Hadrup, Lars Rønn Olsen, Jane Skjoeth-Rasmussen, David Scheie, Olga Østrup, Hans Skovgaard Poulsen, Ulrik Lassen
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma multiforme (GBM) is an aggressive brain tumor with a poor prognosis. Standard of care at diagnosis is surgical resection, followed by radiation and temozolomide. Receiving this therapy, the median survival is 14.6 months [1]. We have no standard treatment for relapse and known options have limited effect. There is an urgent need for novel treatment interventions to improve clinical outcomes and quality of life. Recently, improved overall survival has been achieved with immune therapeutics in melanoma and renal cell carcinoma. Accordingly, it has been posited that immunotherapy may offer promise in other difficult cancers such as GBM [2]. We present our translational study; a phase II open label, two-armed translational study of Nivolumab and Bevacizumab for recurrent GBM, who have failed Stupp’s regime [1]. Patients are included in two arms depending on possibly salvage neurosurgical resection. Both arms receive Nivolumab and Bevacizumab administrated every second weekend, but the surgical arm also receive Nivolumab 7 days prior surgery. We expect 40 patients; 20 in each arm. Enrollment period is expected to 20 months, started October 2018. Our primary objective is to make preliminary assessment of immune related biomarkers, including PD-L1; therefore, we perform full genome sequencing on tumor biopsies from the surgical arm and on blood samples from both arms. We evaluate changes in the transcriptomic landscape caused by the check-point inhibition and relation to response as compared with baseline sequencing data, as well as the impact of tumor mutation burden and neoepitope load. We investigate the tumor microenvironment by harvesting tumor infiltrating lymphocytes and study the composition by flow-cytometry. The patients are evaluated by blood samples, FET-PET as wells as clinical examinations to evaluate PFS and OS. Overall the study will provide us with a unique possibility to investigate and thereof predict which patients will profit from the treatment.
Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials
Authors: Polina Shindiapina, Maciej Pietrzak, Michal Seweryn, Eric McLaughlin, Xiaoli Zhang, Mateusz Makowski, Justin Lyberger, Hsiaochi Chang, Elshafa Hassan Ahmed, Alexander Prouty, Rebecca Pearson, Rhonda Kitzler, Jennifer Le-Rademacher, Richard F. Little, Gorgun Akpek, Ernesto Ayala, Steven Devine, Ariela Noy, Lawrence D Kaplan, Uday Popat, Jack W. Hsu, Lawrence E Morris, Adam M. Mendizabal, Craig C Hofmeister, William Wachsman, Stephen J Forman, Willis H. Navarro, Joseph C. Alvarnas, Richard F. Ambinder, Gregory K. Behbehani, Gerard Lozanski, Robert A Baiocchi
Journal: Blood (2019)
Factor-Associated Risk Factors of Mild Cognitive Impairment in Thalassemia Patients : Probable Role of FGF21
Authors: Wasan Theerajangkhaphichai, Adisak Tantiworawit, Jirapas Sripetchwandee, Nattayaporn Apaijai, Sirawit Sriwichaiin, Napatsorn Saiyasit, Kewarin Jinawong, Busarin Arunsak, Pokpong Piriyakhuntorn, Thanawat Rattanathammethee, Sasinee Hantrakool, Chatree Chai-Adisaksopha, Ekarat Rattarittamrong, Lalita Norasetthada, Pimlak Charoenkwan, Nipon Chattipakorn, Siriporn Chattipakorn
Journal: Blood (2019)
Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study
Authors: Emma L van der Ende, Lieke H Meeter, Jackie M Poos, Jessica L Panman, Lize C Jiskoot, Elise G P Dopper, Janne M Papma, Frank Jan de Jong, Inge M W Verberk, Charlotte Teunissen, Dimitris Rizopoulos, Carolin Heller, Rhian S Convery, Katrina M Moore, Martina Bocchetta, Mollie Neason, David M Cash, Barbara Borroni, Daniela Galimberti, Raquel Sanchez-Valle, Robert Laforce, Fermin Moreno, Matthis Synofzik, Caroline Graff, Mario Masellis, Maria Carmela Tartaglia, James B Rowe, Rik Vandenberghe, Elizabeth Finger, Fabrizio Tagliavini, Alexandre de Mendonça, Isabel Santana, Chris Butler, Simon Ducharme, Alex Gerhard, Adrian Danek, Johannes Levin, Markus Otto, Giovanni B Frisoni, Stefano Cappa, Yolande A L Pijnenburg, Jonathan D Rohrer, John C van Swieten, Martin N. Rossor, Jason D. Warren, Nick C. Fox, Ione O.C. Woollacott, Rachelle Shafei, Caroline Greaves, Rita Guerreiro, Jose Bras, David L. Thomas, Jennifer Nicholas, Simon Mead, Rick van Minkelen, Myriam Barandiaran, Begoña Indakoetxea, Alazne Gabilondo, Mikel Tainta, Maria de Arriba, Ana Gorostidi, Miren Zulaica, Jorge Villanua, Zigor Diaz, Sergi Borrego-Ecija, Jaume Olives, Albert Lladó, Mircea Balasa, Anna Antonell, Nuria Bargallo, Enrico Premi, Maura Cosseddu, Stefano Gazzina, Alessandro Padovani, Roberto Gasparotti, Silvana Archetti, Sandra Black, Sara Mitchell, Ekaterina Rogaeva, Morris Freedman, Ron Keren, David Tang-Wai, Linn Öijerstedt, Christin Andersson, Vesna Jelic, Hakan Thonberg, Andrea Arighi, Chiara Fenoglio, Elio Scarpini, Giorgio Fumagalli, Thomas Cope, Carolyn Timberlake, Timothy Rittman, Christen Shoesmith, Robart Bartha, Rosa Rademakers, Carlo Wilke, Hans-Otto Karnath, Benjamin Bender, Rose Bruffaerts, Philip Vandamme, Mathieu Vandenbulcke, Catarina B. Ferreira, Gabriel Miltenberger, Carolina Maruta, Ana Verdelho, Sónia Afonso, Ricardo Taipa, Paola Caroppo, Giuseppe Di Fede, Giorgio Giaccone, Sara Prioni, Veronica Redaelli, Giacomina Rossi, Pietro Tiraboschi, Diana Duro, Maria Rosario Almeida, Miguel Castelo-Branco, Maria João Leitão, Miguel Tabuas-Pereira, Beatriz Santiago, Serge Gauthier, Sonja Schonecker, Elisa Semler, Sarah Anderl-Straub, Luisa Benussi, Giuliano Binetti, Roberta Ghidoni, Michela Pievani, Gemma Lombardi, Benedetta Nacmias, Camilla Ferrari, Valentina Bessi
Journal: The Lancet Neurology (2019)